Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

143.00 +0.74 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
55 56 Next >
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5% 
Via InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
The pharmaceutical company's growth prospects have taken a big hit. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
 
Via Benzinga
Looking Into Biogen's Recent Short Interest
 
Via Benzinga
Is Sage Therapeutics a Contrarian Buy?
A regulatory setback weighed heavily on the drugmaker's shares Monday. 
Via The Motley Fool
Why Shares of Sage Therapeutics Slumped This Week
The company got bad news from the FDA and saw increased losses. 
Via The Motley Fool
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
The company's rare disease portfolio may soon get an upgrade. 
Via The Motley Fool
With an Acquisition on the Way, Is Biogen Stock a Buy?
Can the biotech finally get back in the good graces of investors? 
Via The Motley Fool
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
Lilly shares surged 15% in one day to a record high. Here's what you should know. 
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
Biogen Unusual Options Activity For August 02
 
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
 
Via Benzinga
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter 
Via Benzinga
Dow Rises Over 300 Points To Start The Week
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses. 
Via Talk Markets
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
The company gained approval for the first oral treatment for postpartum depression. 
Via Investor's Business Daily
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with  
Via Benzinga
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Biogen Inc.
Via GlobeNewswire
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now
Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites. 
Via InvestorPlace
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)
From Brodsky & Smith LLC
Via GlobeNewswire
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen also recently announced a plan to cut costs and focus investment on high-growth areas. 
Via The Motley Fool
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
 
Via Benzinga
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
By 2024, their medicines will likely be competing on the market, and one might win. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.